Please select the option that best describes you:
How are you using liquid biopsy in the routine management of your patients with metastatic NSCLC?
Are you using ctDNA blood tests for targetable mutations at the time of diagnosis, at the time of disease progression, or not at all?
Answer from: Medical Oncologist at Academic Institution
The dramatic improvement in the prognosis of metastatic NSCLC patients harboring targetable oncogenic genetic alterations with highly effective therapy has underscored the need for tumor molecular profiling. There have been numerous studies in the past decade assessing the performance of ctDNA (here...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Circulating tumor DNA testing has quickly become an important part of my algorithms. At initial diagnosis, if the diagnostic specimen is cytologic, or a bone specimen (which often give indeterminate or false negative mutation results), or has been exhausted, ctDNA is a reasonable approach which can ...